Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis
Status:
Terminated
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase I trial is studying the side effects and best dose of sorafenib in
treating patients with locally advanced or metastatic liver cancer and cirrhosis.